1652 related articles for article (PubMed ID: 20811725)
61. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
[TBL] [Abstract][Full Text] [Related]
62. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
63. 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.
Estañ MC; Calviño E; de Blas E; Boyano-Adánez Mdel C; Mena ML; Gómez-Gómez M; Rial E; Aller P
Biochem Pharmacol; 2012 Dec; 84(12):1604-16. PubMed ID: 23041229
[TBL] [Abstract][Full Text] [Related]
64. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS
Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281
[TBL] [Abstract][Full Text] [Related]
65. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
[TBL] [Abstract][Full Text] [Related]
66. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
67. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.
Hong Z; Xiao M; Yang Y; Han Z; Cao Y; Li C; Wu Y; Gong Q; Zhou X; Xu D; Meng L; Ma D; Zhou J
Carcinogenesis; 2011 Oct; 32(10):1550-8. PubMed ID: 21803735
[TBL] [Abstract][Full Text] [Related]
68. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
69. Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells.
Kang JI; Hong JY; Lee HJ; Bae SY; Jung C; Park HJ; Lee SK
PLoS One; 2015; 10(12):e0144368. PubMed ID: 26656173
[TBL] [Abstract][Full Text] [Related]
70. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
71. Interruption of mitochondrial complex IV activity and cytochrome c expression activated O₂·⁻-mediated cell survival in silibinin-treated human melanoma A375-S2 cells via IGF-1R-PI3K-Akt and IGF-1R-PLC γ-PKC pathways.
Jiang YY; Huang H; Wang HJ; Wu D; Yang R; Tashiro S; Onodera S; Ikejima T
Eur J Pharmacol; 2011 Oct; 668(1-2):78-87. PubMed ID: 21703257
[TBL] [Abstract][Full Text] [Related]
72. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
73. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.
Vucicevic L; Misirkic M; Janjetovic K; Vilimanovich U; Sudar E; Isenovic E; Prica M; Harhaji-Trajkovic L; Kravic-Stevovic T; Bumbasirevic V; Trajkovic V
Autophagy; 2011 Jan; 7(1):40-50. PubMed ID: 20980833
[TBL] [Abstract][Full Text] [Related]
74. Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway.
Carlson CB; Robers MB; Vogel KW; Machleidt T
J Biomol Screen; 2009 Feb; 14(2):121-32. PubMed ID: 19196698
[TBL] [Abstract][Full Text] [Related]
75. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
[TBL] [Abstract][Full Text] [Related]
76. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition.
Sun H; Yu T; Li J
Cancer Lett; 2011 Nov; 310(1):118-28. PubMed ID: 21775054
[TBL] [Abstract][Full Text] [Related]
77. Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles.
Kumar VB; Yuan TC; Liou JW; Yang CJ; Sung PJ; Weng CF
Mutat Res; 2011 Feb; 707(1-2):42-52. PubMed ID: 21185843
[TBL] [Abstract][Full Text] [Related]
78. Activation of AMPK α2 inhibits airway smooth muscle cells proliferation.
Liu L; Pan Y; Song Y; Su X; Ke R; Yang L; Gao L; Li M
Eur J Pharmacol; 2016 Nov; 791():235-243. PubMed ID: 27600020
[TBL] [Abstract][Full Text] [Related]
79. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
80. Involvement of PI3K-AKT-mTOR pathway in protein kinase CKII inhibition-mediated senescence in human colon cancer cells.
Park JH; Kim JJ; Bae YS
Biochem Biophys Res Commun; 2013 Apr; 433(4):420-5. PubMed ID: 23523798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]